Previous 10 | Next 10 |
RADNOR, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christophe...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix...
MacroGenics (NASDAQ: MGNX ) +121% on positive margetuximab data . More news on: MacroGenics, Inc., Snap Inc., Zendesk, Inc., Stocks on the move, Read more ...
RADNOR, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today an...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +34.76% Cumulative Gain by Friday of the Week: -1.97% We are still seeing that selling the breakout stocks prior to the end of the fixed 5-day measurement period is the most profitable 1 week strategy. Also as I...
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star Bu...
RADNOR, Pa., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today an...
by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any...
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
Gainers: PSDO +9.1% . ASNS +4.9% . TVIX +4.6% . MRNS +3.1% . M +1.6% . More news on: Presidio, Arsanis, Inc., VelocityShares Daily 2x VIX Short-Term ETN, , Stocks on the move, News on ETFs, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...